<DOC>
	<DOCNO>NCT00848510</DOCNO>
	<brief_summary>This study intend test experimental drug call EMD 525797 ( Abituzumab ) . This drug yet approve sale test small number people date ( prior study start another research study carry involve 37 healthy volunteer receive study drug ) . Until know study drug , use research study . This research study plan answer important question study drug tolerate may work subject ovarian colorectal cancer spread liver ( i.e . metastatic cancer ) . The Sponsor ( Merck KGaA ) study develop study drug .</brief_summary>
	<brief_title>EMD 525797 Colorectal Ovarian Cancer Patients With Liver Metastases</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Provision sign write informed consent Male female subject , age least 18 year Subjects liver metastasis ( 3 10 centimeter [ cm ] diameter ) colorectal ovarian cancer Failure standard cancer therapy Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 study entry estimate life expectancy least 3 month Adequate haematological function , define absolute neutrophil count ( ANC ) great equal ( &gt; = ) 1.5 x 10^9 per liter ( /L ) , platelet count &gt; = 100 x 10^9 / L , haemoglobin concentration &gt; = 9 gram per deciliter ( g/dL ) As subject document liver metastasis treat trial , liver function test value accept follow : upper limit Grade 2 defined National Cancer Institute Common Terminology Criteria Adverse Events ( NCI CTCAE ) Version 3.0 . This include total bilirubin level less equal ( = &lt; ) 3 time upper limit normal ( ULN ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) level = &lt; 5 x ULN Adequate renal function define serum creatinine = &lt; 1.5 x ULN creatinine clearance &gt; =50 milliliter per minute ( mL/min ) calculate CockcroftGault Effective contraception ( example : double barrier method ) male female subject risk conception exists . These subject must willing avoid pregnancy study ( screen end study [ EOS ] ) well least 3 month last dosing . Any systemic cancer treatment within 30 day treatment EMD 525797 Thrombolytics oral parenteral anticoagulant ( except maintain patency preexisting , permanent indwell intravenous catheter ) within 10 day prior study start treatment Radiotherapy , chemotherapy , surgery , investigational drug 30 day start treatment study , and/or diagnostic biopsy within 2 week start treatment study Previous treatment antiintegrin therapy anti angiogenic therapy within last 6 month Confirmed clinically suspect brain metastasis Known hypersensitivity reaction study medication History allergic reaction monoclonal antibody ( mAb ) therapy Uncontrolled hypertension ( systolic blood pressure great ( &gt; ) 180 millimeter mercury ( mmHg ) , diastolic &gt; 100 mmHg ) Current history chronic daily aspirin therapy ( dose = &lt; 150 mg permit ) , bleed disorder , and/or history thromboembolic event Severe peripheral vascular disease ulceration Unstable angina pectoris , myocardial infarction within 6 month start study treatment , clinical significant abnormal electrocardiogram ( ECG ) screening ; In woman childbearing potential , pregnancy ( absence confirm beta human chorionic gonadotropin [ Î² HCG ] test , unless subject previously undergone hysterectomy bilateral ovariectomy ) , lactation period Known alcohol drug abuse Participation another clinical trial within past 30 day start study treatment All significant disease , opinion principal investigator ( PI ) , might impair subject 's tolerance study treatment Dementia , alter mental status , psychiatric condition would prohibit understanding rendering informed consent Legal incapacity limit legal capacity ( applicable rare case ) Known human immuno deficiency ( HIV ) infection and/or active hepatitis B C virus infection Ongoing uncontrolled infection Contraindications magnetic resonance imaging ( MRI )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>